Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common subtype of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….
Search results for: fractures
Case Report: Reactive Arthritis Following COVID-19
SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…
Untangling the Diagnosis & Management of GCA
Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.
Bipartisan DXA Bill Under Consideration in Congress
The Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act would set a $98 floor for Medicare reimbursement for the dual-energy X-ray absorptiometry (DXA) bone density test.
Do Bisphosphonates Reduce Cardiovascular-Related Mortality?
It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteoporosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…
The Character of Rheumatology Has Changed Over the Past 50 Years
Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheumatology in the halcyon days of the 1970s and 80s. That’s not to belittle the world we now live in, with so many treatment options for our…
Denosumab Promising for Osteolysis after Total Hip Replacement
NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…
Therapeutic Exercise for Bone Health
ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
Osteoporosis Experts Discuss Bisphosphonate Holidays
ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 26
- Next Page »